Key Takeaways
J&J is hoping to push its way into atopic dermatitis despite the competitive market dynamics.
The company is progressing multiple bispecific antibodies that it gained through business development deals earlier this year.
J&J immunodermatology disease area leader Liza O’Dowd talked to Scrip about J&J’s interest in the therapeutic area and how bispecific antibodies could represent a novel approach.
Johnson & Johnson has a proven track record in immunology with the development of mega-brands like Remicade (infliximab), Stelara (ustekinumab),...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
